Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?

Main Article Content

Carlos José Marinho Figueiredo - Corresponding Author

Carlos M. Figueiredo [carlos.figueiredo.1993@gmail.com]
Rua Norton de Matos, 300, 4760-157 Vila Nova de Famalicão, Portugal

José Diogo Silva Castro Faria Freitas
Maria do Céu Ferreira

Abstract

Selective serotonin reuptake inhibitors antidepressants are psychopharmaceuticals frequently used in clinical practice in the fields of General Practice and Psychiatry for the treatment of depressive and anxiety disorders. The high prescription of this class of antidepressants results from their profile of efficacy, safety and tolerability.
It is clinically consensual that this pharmacological class can interfere with the various phases of the sexual response during antidepressant treatment. However, more and more cases have been reported in the literature, in which sexual dysfunction is not reversible after discontinuation of the drug, configuring a new persistent clinical entity, whose pathophysiological substrate is currently under intense scientific investigation. Reviewing the recent published literature in this matter and raising awareness of physicians about this new entity reveals itself as a priority with potential implications, particularly on the approach of psychiatric pathologies so prevalent in the current society.

Keywords: Serotonin Uptake Inhibitors/adverse effect; Sexual Dysfunction, Physiological/chemically induced

Article Details

1.
Marinho Figueiredo CJ, Silva Castro Faria Freitas JD, Ferreira M do C. Persistent Sexual Dysfunction and Selective Serotonin Reuptake Inhibitors: Myth or Reality?. Gaz Med [Internet]. 2022 Sep. 1 [cited 2022 Nov. 30];9(3):230-9. Available from: https://gazetamedica.pt/index.php/gazeta/article/view/572
Section
REVIEW ARTICLES